All News
Risk Factors for Rheumatoid Arthritis-associated Interstitial Lung Disease
Sparks and colleagues have published a matched cohort analysis demonstrating risk factors that may augment the risk of rheumatoid arthritis (RA)-associated interstitial lung disease (ILD), especially the combination of obesity, high CRP, high MD-HAQ and >30 pack-year smoking h
Read ArticleInsurers Bet Big on Bribing Patients
Last month, psoriasis patients covered by Cigna received a curious letter from the insurance giant's pharmacy management division.
Read ArticleAURORA-1: Voclosporin Efficacy in Lupus Nephritis
Lancet has published the results of the AURORA-1 trial, wherein the calcineurin inhibitor, voclosporin, was tested in a placebo controlled trial of lupus nephritis and shown to be effective at inducing a complete renal response.
Read ArticleFDA Advisors Split on Avacopan for Vasculitis
Members of an FDA advisory panel were sharply divided as to whether avacopan, an oral small molecule inhibitor of the C5a receptor, was sufficiently safe and effective for treating antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.
Read ArticleAvacopan for ANCA Vasculitis Goes in Front of the FDA
An FDA advisory panel will consider whether to recommend approval of an oral C5a inhibitor for antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, with agency staff raising questions over the "clinical meaningfulness" of key study data.
Read ArticleRheumNow Podcast – Falling or Falling in Love?
Dr. Jack Cush reviews the best journal articles from the past week on RheumNow.com.
Read ArticleARTIC REWIND - Don't Half DMARD Therapy
The ARTIC-REWIND study examined rheumatoid arthritis (RA) patients in remission on conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) to see if they could "step-down" their csDMARDs theray; but the study showed that 25% those who went on half-dose experienced disease fl
Read ArticleDrug Monitoring Ineffective with Infliximab Treatment
The predictive value of therapeutic drug monitoring (TDM) while on biologics is debateable; gastroenterology routinely relies on TDM, while rheumatologists do not.
Read ArticleResults Disappoint for Fecal Transplant in Arthritis
Fecal microbiota transplantation (FMT) showed disappointing results among patients with active psoriatic arthritis, a small randomized trial found.
Read ArticleRheumNow Podcast – Uppers and Downers
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.
Read ArticleTofacitinib in Ankylosing Spondylitis
A phase III trial assessing the efficacy and safety of tofacitinib in adults with with active ankylosing spondylitis (AS) shows that JAK inhibitiion was superior to placebo in a 48 week study.
Read ArticlePsoriatic Pregnancies Pose Risks to the Mother, Not Child
A metanalysis of pregnancy outcomes in women with psoriasis and psoriatic arthritis finds an excess risk of adverse maternal events, but not adverse neonatal events.
This systematic review included 16 studies meeting inclusion criteria.
Read ArticleDual IL-17 Targeting is Effective but has More Candidiasis
Bimekizumab (BIM) is a monoclonal antibody that targets both interleukin-17A and interleukin-17F, which as a biologic target has worked well in the management of psoriatic disease. The current issue of the NEJM has two reports wherein BIM was shown to be more effective than secukinumab and adalimumab in treating patients with moderate-to-severe plaque psoriasis; however, safety concerns arise.
Read ArticleRheumNow Podcast – Coconspirators: RA and Lung Disease
Dr. Jack Cush reviews and discusses more than a dozen news and journal articles from the past week on RheumNow.com.
Read ArticleBSRBR: Demyelinating Disease Following Anti-TNFα Therapy
Analysis of patients receiving anti–tumor necrosis factor α (TNFi) therapy in the British Society for Rheumatology Biologics Register (BSRBR) shows that the risk of demyelination is rare but is marginally increased by taking TNFi therapy.
Read ArticleIncreased Risk of COPD in ACPA+ Pre-RA Patients
The lung and its pathology is uniquely tied to rheumatoid arthritis (RA) and its pathogenesis. A new study shows that elevation of anti–citrullinated protein antibodies (ACPAs) before diagnosis of RA increases the risk of developing chronic obstructive pulmonary disease (COPD
Read ArticleNew Side Effect From mRNA COVID Vaccines?
Herpes zoster reactivation -- a.k.a. shingles -- following COVID-19 vaccination in six patients with comorbid autoimmune/inflammatory diseases may be a new adverse event associated with the Pfizer/BioNTech mRNA vaccine, suggested a new report.
Read ArticleBroadalumab Efficacy in Axial Spondyloarthritis
Broadalumab (Siliq), an anti-interleukin-17 receptor A monoclonal antibody, is currently FDA- approved for use in adults with plaque psoriasis; but a recent trial shows it to be effective in patients with axial spondyloarthritis (axSpA).
Read Article
Dr. John Cush RheumNow ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)


